Published in Mayo Clin Proc on May 01, 1999
5-Fluorocytosine in human cryptococcosis. Antimicrob Agents Chemother (Bethesda) (1968) 3.08
Progressive disseminated histoplasmosis. A prospective study of 26 patients. Ann Intern Med (1972) 1.99
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
Aspergillus species endocarditis. The new face of a not so rare disease. Am J Med (1974) 1.74
In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda) (1968) 1.62
North American blastomycosis: a study of 40 patients. Medicine (Baltimore) (1968) 1.56
Chemotherapeutic agents for the pulmonary mycoses. Report of the Committee on Fungus Diseases and Subcommittee on Therapy, American College of Chest Physicians. Chest (1971) 1.53
Preliminary studies on a hyphaforming mutant of Cryptococcus neoformans. Mycologia (1966) 1.46
Thoracic cross-sectional imaging of amyloidosis. AJR Am J Roentgenol (1997) 1.35
Meningoencephalitis due to pathogenic free-living amoebae. Report of two cases. JAMA (1968) 1.30
Intraventricular administration of amphotericin B. Use of subcutaneous reservoir in four patients with mycotic meningitis. JAMA (1965) 1.28
5-fluorocytosine in human candidiasis. Antimicrob Agents Chemother (Bethesda) (1970) 1.22
Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest (2001) 1.20
Cryptococcosis complicating sarcoidosis. Am Rev Respir Dis (1973) 1.12
Epidemic of pulmonary blastomycosis (Namekagon fever) in Wisconsin canoeists. Chest (1984) 1.12
Clinical features of extracutaneous sporotrichosis. Medicine (Baltimore) (1967) 1.08
Flucytosine. N Engl J Med (1972) 1.04
Therapeutic bronchoscopy in broncholithiasis. Am J Respir Crit Care Med (1999) 1.04
Risk of osteoporotic fractures in women with breast cancer: a population-based cohort study. J Chronic Dis (1987) 0.99
Clinical and laboratory studies of a new micronized preparation of hamycin in systemic mycoses in man. Antimicrob Agents Chemother (Bethesda) (1967) 0.99
External-beam radiation therapy in the treatment of diffuse tracheobronchial amyloidosis. Mayo Clin Proc (2001) 0.99
Meningoencephalitis due to hyphae-forming Cryptococcus neoformans. Am J Clin Pathol (1971) 0.99
Sarcoidosis presenting as a central nervous system mass lesion. Chest (1997) 0.97
Brain abscess caused by Cladosporium trichoides. Arch Intern Med (1976) 0.97
Cavitary pulmonary infarct in immunocompromised hosts. Mayo Clin Proc (1995) 0.97
Pulmonary hypertension in patients with amyloidosis. Chest (2001) 0.97
Cardiac echinococcosis: case report of unusual echocardiographic appearance. Mayo Clin Proc (1995) 0.91
Chemotherapy for the systemic mycoses: the prelude to ketoconazole. Rev Infect Dis (1981) 0.90
New drugs for the systemic mycoses: flucytosine and clotrimazole. Bull N Y Acad Med (1975) 0.89
Chemotherapy of the systemic mycoses. Med Clin North Am (1982) 0.88
Hamycin: chemotherapeutic studies in systemic mycoses of man. Am Rev Respir Dis (1967) 0.88
Viruria in man, an update. Prog Med Virol (1974) 0.88
In vitro and in vivo activity of hamycin against Blastomyces dermatitidis. J Bacteriol (1969) 0.86
Candida meningitis. Arch Intern Med (1966) 0.85
Cryptococcus neoformans osteomyelitis: case report of two patients. Sabouraudia (1974) 0.83
Cryptococcal pyelonephritis. N Engl J Med (1968) 0.82
The current status of chemotherapeutic agents for the systemic mycoses. Contrib Microbiol Immunol (1977) 0.81
Pulmonary infection due to opportunistic fungi. Adv Intern Med (1970) 0.79
Pediatric tracheobronchial foreign bodies. A case report. Minn Med (1993) 0.78
Fungal infections of the central nervous system. Clin Neurosurg (1966) 0.76
Histoplasma and cryptococcus meningitis. Res Publ Assoc Res Nerv Ment Dis (1968) 0.76
Troubles in sporotrichosis. N Engl J Med (1969) 0.75
Cryptococcus neoformans and cryptococcosis. Trans Am Clin Climatol Assoc (1970) 0.75
In Vivo Susceptibility of Cryptococcus neoformans to Hamycin, Amphotericin B, and 5-Fluorocytosine. Infect Immun (1970) 0.75
50-year-old man with fever and rhinorrhea. Mayo Clin Proc (1995) 0.75
To dig I am not able. N Engl J Med (1972) 0.75
Recognition and current management of the systemic mycoses. Med Clin North Am (1967) 0.75
Indications for chemotherapy in the pulmonary mycoses. A report of the Committee on Fungus Diseases, Subcommittee on Therapy, American College of Chest Physicians. Dis Chest (1969) 0.75
Sarah Elizabeth Stewart. Cancer Res (1977) 0.75
Chemotherapy of the systemic mycoses. Am Fam Physician (1973) 0.75
Current and future chemotherapy of central nervous system fungal infections. Adv Neurol (1974) 0.75
Factors predisposing to illness. Mod Treat (1970) 0.75
Round table on antifungal agents. Antimicrob Agents Chemother (Bethesda) (1965) 0.75
Assay of antifungal agent saramycetin (X-5079C) in patient body fluids. Am Rev Respir Dis (1969) 0.75
Hamycin toxicity in the dog. Antimicrob Agents Chemother (Bethesda) (1965) 0.75
Reducing amphotericin B reactions. 3. Use of a preparation with increased phosphate buffer. Am Rev Respir Dis (1965) 0.75
Pulmonary lymphoproliferative disorders. Mayo Clin Proc (1993) 0.75
Antimicrobial therapy in systemic fungal infections. Am J Med (1965) 0.75
The polypeptide antifungal agent (X-5079C): further studies in 39 patients. Am Rev Respir Dis (1966) 0.75
Fungal infections. Clin Pharmacol Ther (1974) 0.75